ImageneBio Inc

ImageneBio Inc reported a net loss of $45.3 million for fiscal year 2025, with minimal revenue of $800,000 from license agreements. The company incurred significant operating expenses totaling $49.3 million, primarily driven by research and development costs of $28.5 million and general and administrative expenses of $20.7 million. Despite the operating loss of $48.5 million, the company generated $2.8 million in other income, primarily from interest income. The balance sheet shows strong liquidity with $94.5 million in cash and cash equivalents and $40.8 million in marketable securities, resulting in total current assets of $140.3 million. The company's cash position improved significantly with a net increase of $82.4 million in cash and cash equivalents, largely due to $135.5 million in net cash provided by financing activities including PIPE financing and term loan proceeds. The company's accumulated deficit stands at $230.1 million, reflecting its development-stage status.

Key Takeaways